Tactile Systems TechnologyTCMD
TCMD
About: Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.
Employees: 1,037
0
Funds holding %
of 7,336 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
844% more call options, than puts
Call options by funds: $1.89M | Put options by funds: $200K
3.42% more ownership
Funds ownership: 87.9% [Q4 2024] → 91.32% (+3.42%) [Q1 2025]
0% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 22
1% less funds holding
Funds holding: 141 [Q4 2024] → 139 (-2) [Q1 2025]
15% less repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 52
21% less capital invested
Capital invested by funds: $361M [Q4 2024] → $285M (-$76.6M) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$13
3%
upside
Avg. target
$13
3%
upside
High target
$13
3%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
B. Riley Securities Kyle Bauser | 3%upside $13 | Neutral Maintained | 5 Aug 2025 |
Financial journalist opinion
Based on 9 articles about TCMD published over the past 30 days
Positive
Zacks Investment Research
6 days ago
Is Tactile Systems Technology (TCMD) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Positive
Zacks Investment Research
6 days ago
Tactile Systems Technology (TCMD) Just Overtook the 20-Day Moving Average
Tactile Systems Technology (TCMD) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, TCMD broke through the 20-day moving average, which suggests a short-term bullish trend.
Positive
Zacks Investment Research
6 days ago
Tactile Systems Technology (TCMD) Recently Broke Out Above the 50-Day Moving Average
Tactile Systems Technology (TCMD) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, TCMD broke out above the 50-day moving average, suggesting a short-term bullish trend.
Neutral
Seeking Alpha
1 week ago
Tactile Systems Technology, Inc. (TCMD) Q2 2025 Earnings Call Transcript
Tactile Systems Technology, Inc. (NASDAQ:TCMD ) Q2 2025 Earnings Conference Call August 4, 2025 5:00 PM ET Company Participants Elaine M. Birkemeyer - Chief Financial Officer Sheri Louise Dodd - CEO, President & Director Conference Call Participants Anderson Schock - B.
Positive
Zacks Investment Research
1 week ago
Tactile Systems Technology (TCMD) Surpasses Q2 Earnings and Revenue Estimates
Tactile Systems Technology (TCMD) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.2 per share a year ago.
Neutral
The Motley Fool
1 week ago
Tactile Systems (TCMD) Q2 Revenue Up 8%
Tactile Systems (TCMD) Q2 Revenue Up 8%
Neutral
GlobeNewsWire
1 week ago
Tactile Systems Technology, Inc. Reports Second Quarter 2025 Financial Results
MINNEAPOLIS, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Summary & Recent Business Highlights: Total revenue increased 7.8% year-over-year to $78.9 million Gross margin of 75% versus 74% in Q2 2024 Net income of $3.2 million versus $4.3 million in Q2 2024 Adjusted EBITDA of $7.7 million versus $9.1 million in Q2 2024 Announced the presentation of new data demonstrating significant benefits associated with use of Flexitouch Plus in treating patients with head and neck cancer-related lymphedema Repurchased $16.5 million of stock to complete the Company's share repurchase program “We delivered strong financial performance in the second quarter, marked by total revenue growth of nearly 8% year-over-year and ahead of our previously stated expectations,” said Sheri Dodd, Chief Executive Officer of Tactile Medical.
Neutral
GlobeNewsWire
3 weeks ago
Tactile Medical to Release Second Quarter of Fiscal Year 2025 Financial Results on August 4, 2025
MINNEAPOLIS, July 21, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that second quarter of fiscal year 2025 financial results will be released after the market closes on Monday, August 4, 2025.
Positive
MarketBeat
4 weeks ago
3 Small Caps Drawing Insider and Institutional Support
After lagging behind large-cap peers for the past two years, small-cap stocks may finally be poised for a breakout in the second half of 2025. With interest rate cuts potentially on the horizon, improving macroeconomic conditions, and attractive relative valuations, institutional investors are beginning to rotate into this overlooked segment of the market.
Neutral
GlobeNewsWire
2 months ago
New Data Demonstrates Significant Clinical and Quality-of-Life Benefits of Flexitouch® Plus in Treating Lymphedema Among Head and Neck Cancer Survivors
Abstract Presented at ASCO 2025 Annual Meeting Features Two-Month Data from the Largest Randomized Trial Ever Conducted Among Head and Neck Cancer Survivors Abstract Presented at ASCO 2025 Annual Meeting Features Two-Month Data from the Largest Randomized Trial Ever Conducted Among Head and Neck Cancer Survivors
Charts implemented using Lightweight Charts™